Post by madog365 on Mar 23, 2016 14:59:55 GMT -5
Going to throw out another guess as to the identity of Sean Cunningham.
--
Sean Cunningham, Managing Director, GTCR
Bio:
Sean joined GTCR in 2001 and is currently a Managing Director of the firm. He was previously a consultant with The Boston Consulting Group. Sean holds an MBA from the Wharton School at the University of Pennsylvania as well as AB and BE degrees in Engineering Sciences from Dartmouth College. Sean currently is a director of Cedar Gate Technologies, Cole-Parmer, Cord Blood Registry, Correct Care Solutions, Devicor Medical Products, Maravai Life Sciences and Sterigenics. He was instrumental in GTCR’s investment in Ovation Pharmaceuticals.
--
GTCR LLC is a private equity firm focused on leveraged buyout, leveraged recapitalization, growth capital and rollup transactions. Since 1980, GTCR has invested more than $10 billion in over 200 companies.
--
Maravai Life Sciences:
Maravai LifeSciences was formed in March 2014 as a partnership among Carl Hull and Eric Tardif -- proven leaders in the life sciences industry -- and GTCR, a leading private equity firm.
Maravai’s mission is to build a transformative company in the in vitro diagnostics and life sciences tools markets by acquiring outstanding businesses in these spaces and accelerating their growth. We do this through direct cash investments in their existing operations, by acquiring complementary businesses or product lines and by contributing our proven operating expertise.
www.maravai.com/ - built via squarespace
--
Recent news from GTCR 2/4/2016: exithub.com/gtcr-fiorentino-launch-tersera-therapeutics-pharmaceutical-pe-startup/
"GTCR, a leading private equity firm, said it has entered into a partnership with Ed Fiorentino to form TerSera Therapeutics LLC. The new company will focus on acquiring specialty pharmaceutical companies and products as part of a strategy to build a leading company in the industry.
Initial target acquisition opportunities include products which are already approved or currently marketed, as well as late-stage development assets. GTCR’s investment in TerSera will be made from GTCR Fund XI, a private equity fund with $3.85 billion of limited partner equity capital commitments. Fiorentino will serve as TerSera’s chairman and CEO.
TerSera is the third partnership between GTCR and Fiorentino. Previously, he served as chairman and CEO of Crealta Pharmaceuticals LLC, a GTCR-funded specialty pharmaceutical company which was acquired in January 2016 by Horizon Pharma plc. Through organic growth initiatives and four transactions, Crealta built a unique specialty pharmaceutical company focused on niche therapeutic markets within rheumatology and the central nervous system (CNS)."
--
Sean Cunningham, Managing Director, GTCR
Bio:
Sean joined GTCR in 2001 and is currently a Managing Director of the firm. He was previously a consultant with The Boston Consulting Group. Sean holds an MBA from the Wharton School at the University of Pennsylvania as well as AB and BE degrees in Engineering Sciences from Dartmouth College. Sean currently is a director of Cedar Gate Technologies, Cole-Parmer, Cord Blood Registry, Correct Care Solutions, Devicor Medical Products, Maravai Life Sciences and Sterigenics. He was instrumental in GTCR’s investment in Ovation Pharmaceuticals.
--
GTCR LLC is a private equity firm focused on leveraged buyout, leveraged recapitalization, growth capital and rollup transactions. Since 1980, GTCR has invested more than $10 billion in over 200 companies.
--
Maravai Life Sciences:
Maravai LifeSciences was formed in March 2014 as a partnership among Carl Hull and Eric Tardif -- proven leaders in the life sciences industry -- and GTCR, a leading private equity firm.
Maravai’s mission is to build a transformative company in the in vitro diagnostics and life sciences tools markets by acquiring outstanding businesses in these spaces and accelerating their growth. We do this through direct cash investments in their existing operations, by acquiring complementary businesses or product lines and by contributing our proven operating expertise.
www.maravai.com/ - built via squarespace
--
Recent news from GTCR 2/4/2016: exithub.com/gtcr-fiorentino-launch-tersera-therapeutics-pharmaceutical-pe-startup/
"GTCR, a leading private equity firm, said it has entered into a partnership with Ed Fiorentino to form TerSera Therapeutics LLC. The new company will focus on acquiring specialty pharmaceutical companies and products as part of a strategy to build a leading company in the industry.
Initial target acquisition opportunities include products which are already approved or currently marketed, as well as late-stage development assets. GTCR’s investment in TerSera will be made from GTCR Fund XI, a private equity fund with $3.85 billion of limited partner equity capital commitments. Fiorentino will serve as TerSera’s chairman and CEO.
TerSera is the third partnership between GTCR and Fiorentino. Previously, he served as chairman and CEO of Crealta Pharmaceuticals LLC, a GTCR-funded specialty pharmaceutical company which was acquired in January 2016 by Horizon Pharma plc. Through organic growth initiatives and four transactions, Crealta built a unique specialty pharmaceutical company focused on niche therapeutic markets within rheumatology and the central nervous system (CNS)."